Pharmaceuticals
Importation Will Not Lower Drug Costs
Citizens Against Government Waste (CAGW) was disappointed to see that the Trump Administration announced on Thursday, July 19, that the Food and Drug Administration (FDA) is exploring ways to import lower cost
President Trump’s Blueprint to Lower Drug Costs: A Lot to Unpack
On Friday, May 11, President Trump released his report on what his administration will do to lower drug costs.
President Trump's Drug Costs Proposals Coming Soon
The President has already made some good policy decisions and has offered other proposals that will help to lower drug costs.
Stealing Patents Won’t Bring Down Drug Costs
On February 15, 2018, 18 Democratic members of Congress sent a letter to Health and Human Services (HHS) Secretary Alex Azar, asking him to use his authority under 28 U.S.C.
Drug Prices - The Council of Economic Advisers and Trump Administration Weigh In
Last Friday, on February 9, 2018, the White House Council of Economic Advisers released a 30-page report on, “Reforming Biopharmaceutical Pricing at Home and Abroad.
Taxpayers and Patients Win First Round on 340B Drug Discount Rule
Citizens Against Government Waste (CAGW) discussed in its November 7, 2017 WasteWatcher blog, a Centers for Medicare and Medicaid Services (CMS) final rule for Medicare Part B that will lower costs to taxp
Rogue "Drug" Companies Face Congress
On Thursday, February 4, the House Committee on Oversight and Government Reform held a hearing entitled, “Developments in the Prescription Drug Market.”
Judge Tells Federal Agency to Obey the Law for Drug Discount Program
On October 14, the United States District Court for the District of Columbia struck down the Health Resources and Services Administration’s (HRSA) interpretive rule that ordered pharmaceutical manufacturers to provide substantial drug discounts...
More of the Same
Presidential candidate and former-Secretary of State Hillary Clinton proposed several worn-out initiatives this Tuesday that would supposedly lower drug prices but, if implemented, would seriously damage research and development in the United States...
Disappointing News on INNs from the FDA
You may recall I have written about the World Health Organization’s (WHO) naming system for drugs, called the International Non-Proprietary Name or INN, in a January 15, 2015 Swine Line
Howard Dean is Correct
It is not too often that I agree with former Vermont Governor and Democratic presidential candidate Howard Dean but when it comes to the government “negotiating” drug prices in Medicare Part D, he is correct.
More Proof the 340B Program Needs Reform
On July 6, the Government Accountability Office (GAO), the independent, non-partisan investigative arm of Congress, released a report entitled, “Medicare Part B Drugs: Action Needed to Reduce Financial Incentives to Prescribe 340B Drugs at Pa
